Abstract: Methods and systems for the detection and quantification of multiplicity of ionic analytes comprising bromide, phosphate, sulfite, thiosulfate, thiocyanate, and formate, and optionally fluoride, chloride, chromate, selenate, perchlorate, nitrate, nitrite, and sulfate, using ion chromatography and suppressed ion conductivity. The method comprises loading a sample loop with a sample; injecting the sample from the sample loop into a column with an eluent, wherein the column comprises a guard column and an analytical column; separating, with the column, the injected sample at an effective separation temperature the injected sample in the presence of an organic modifier into a multiplicity of detectable ionic analytes; suppressing, with a suppressor, background signal; and detecting, with a detector, the multiplicity of ionic analytes.

Abstract: The present invention is directed to systems and methods for removing trichloroethane (TCA), trichloroethene (TCE), and 1,4-dioxane (1,4-D) from contaminated water and wastewater. The system and methods relying on catalyst reduction of TCA and TCE, and the reduced products are degraded by microorganisms that are capable of biodegrading ethane and 1,4-D. In certain embodiments, a catalyst film comprises precious nanoparticles with diameters of 5-40 nm and a biofilm comprising microorganisms that are capable of degrading ethane and 1,4-D are used in a dual-reactor system to remove TCA, TCE, and 1,4-D from contaminated water and wastewater.

Abstract: The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteroides and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes.

Abstract: The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteriodes and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes.

Abstract: The present invention relates to systems and methods for removing and recovering precious metals, such as platinum-group metals (PGMs), including palladium, from wastewater and waste streams. The invention also relates to systems and methods for recycling the recovered precious metals for catalytic applications.

Abstract: Provided herein are compositions and methods for treating Pitt Hopkins Syndrome (PTHS) by restoring PTHS patient's gut microbiota. These methods can be used with PTHS patient with or without ongoing gastrointestinal symptoms. The methods comprise administering a therapeutic composition comprising a fecal microbe or a fecal microbe preparation to the subject.

Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for modulating the abundance of one or more gut microorganisms in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a fecal microbe preparation to achieve at least a 2-fold change of the abundance of said one or more fecal microorganisms, wherein said one or more gut microorganisms are selected from the group consisting of Bifidobacterium, Prevotella, Desulfovibrio, Copprococcus, Clostridium, and Bacteroides.

Abstract: Provided herein are metabolites and methods of using the metabolites for diagnosing and treating Autism Spectrum Disorder (ASD) in a subject with a gastrointestinal problem, for determining a personalized treatment protocol for the subject, and for monitoring the therapeutic effect of an ASD treatment protocol in the subject being treated with the ASD treatment protocol.

Abstract: Methods and systems for the detection and quantification of multiplicity of ionic analytes comprising CrO42?, AsO43?, SeO42?, and ClO4?, and optionally F?, Cl?, NO2?, NO3?, SO42?, using ion chromatography and suppressed ion conductivity. The method comprises loading a sample loop with a sample; injecting the sample from the sample loop into a column with an eluent, wherein the column comprises a guard column and an analytical column; separating, with the column, the injected sample at an effective separation temperature the injected sample in the presence of an organic modifier into a multiplicity of detectable ionic analytes; suppressing, with a suppressor, background signal; and detecting, with a detector, the multiplicity of ionic analytes.

Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.

Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.

Abstract: The present disclosure is directed toward membrane biofilm reactors primarily comprising microorganisms that produce chemical fuel products or precursors thereof. Reactors of the present disclosure can primarily comprise acetogens, a methanotrophs, and/or Methanosarcina acetivorans.

Abstract: The present invention relates to systems and methods for removing and recovering precious metals, such as platinum-group metals (PGMs), including palladium, from wastewater and waste streams. The invention also relates to systems and methods for recycling the recovered precious metals for catalytic applications.

Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.

Abstract: The present disclosure relates to methods and compositions suitable for changing metabolite levels in a subject in need thereof. In particular, this application provides methods and compositions for changing metabolite levels in a subject diagnosed with Autism Spectrum Disorder (ASD). Methods of preventing or treating an ASD in a subject thereof, as well as methods of selecting a treatment plan for treating an ASD in a subject are also provided.

Abstract: The present disclosure is directed toward membrane biofilm reactors primarily comprising microorganisms that produce chemical fuel products or precursors thereof. Reactors of the present disclosure can primarily comprise acetogens, a methanotrophs, and/or Methanosarcina acetivorans.

Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.

Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.

Abstract: A membrane biofilm reactor including a vessel defining a volume is disclosed. The reactor also typically includes a first and second plurality of hollow fiber membranes. Each hollow fiber membrane generally has an outer surface and a lumen, and is located within the volume. The reactor further preferably includes a first and second gas feedstock. The first gas feedstock is provided through a first inlet in fluid communication with the lumens of the first plurality of hollow fiber membranes. The second gas feedstock is provided through a second inlet in fluid communication with the lumens of the second plurality hollow fiber membranes. Finally, the reactor also typically includes a biofilm formed on the outer surface of the hollow fiber membranes and made up of methanotrophs, Methanosarcina acetivorans, or both. The first gas feedstock is preferably different from the second gas feedstock.

Abstract: The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteriodes and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes.